Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
VKTX
#1456
Viking Therapeutics, Inc
35.5
2
USD
+1.46%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+1.46%
Changement Mensuel
+0.62%
Evolution sur 6 mois
+5.65%
Changement Annuel
+44.68%
Clôture Précédente
35.0
1
Open
35.5
2
Bid
Ask
Low
35.5
2
High
35.5
2
Volume
94
Marchés
Actions des Marchés US
Soins de Santé
VKTX
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
74.13 M
78.36 M
78.42 M
100.49 M
112.25 M
115.55 M
—
Valuation ratios
Enterprise value
388.25 M
334.1 M
631.49 M
1.78 B
4.49 B
3.9 B
12.39 B
Price to earnings ratio
-10.35
-6.46
-9.47
-20.09
-39.84
-11.03
-61.39
Price to sales ratio
—
—
—
—
—
—
—
Price to cash flow ratio
-18.77
-7.46
-13.53
-23.5
-49.98
-14.22
-66.61
Price to book ratio
1.67
1.76
4.5
4.95
4.98
6.2
8.71
Enterprise value to EBITDA ratio
—
—
—
-16.34
-26.7
-9.68
-46.75
Profitability ratios
Return on assets %
-0.15
-0.26
-0.41
-0.23
-0.12
-0.5
-0.47
Return on equity %
-0.16
-0.27
-0.47
-0.25
-0.12
-0.56
-0.51
Return on invested capital %
-11.89 K
-50 K
-28.78 K
-23.85 K
-37.93 K
-169 K
-163.15 K
Gross margin %
—
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
21.12
23.98
7.61
19.19
33.09
9.33
107.78
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.3
-0.62
-0.63
-0.78
-0.81
-2.47
-2.48
EBIT per share
-0.59
-0.72
-0.92
-1.07
-1.38
-3.49
-3.5
EBITDA per share
—
—
—
-1.16
-1.54
-3.57
-3.58
Total debt per share
—
—
—
—
—
—
—
Cash per share
3.42
2.62
2.02
3.84
8.28
6.26
27.43
Net current asset value per share
3.53
2.73
2.17
3.89
8.32
6.35
28.03
Tangible book value per share
3.37
2.62
1.89
3.69
8.07
5.67
26.67
Working capital per share
3.36
2.61
1.89
3.69
8.07
5.67
26.66
Book value per share
3.37
2.62
1.89
3.69
8.07
5.67
26.67
Nouvelles
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
Viking Therapeutics, Inc. (VKTX) Surpasses Market Returns: Some Facts Worth Knowing
NVO Crashes 36% in 3 Months: Is This an Indication to Sell the Stock?
LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships
3 Best Stocks Under $50 to Buy in April 2026, According to Analysts - TipRanks.com
Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks
VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug
William Blair maintient sa recommandation sur Viking Therapeutic suite aux progrès cliniques
Morgan Stanley réitère sa note sur Viking Therapeutics après les progrès de l’essai